Clinical trial for cystic fibrosis drug


SALT LAKE CITY, Nov 16, 2009 (UPI via COMTEX) -- A new drug undergoing a
clinical trial at the University of Utah could help some cystic fibrosis
patients' daily life and longevity, researchers said.

Cystic fibrosis is a genetic condition that causes cells to improperly
manufacture a protein resulting in the production of a thick, sticky mucus that
clogs and damages lungs and causes digestion problems.

Traditional cystic fibrosis drugs treat the symptoms of digestion problems and
lung mucus buildup.

However, the new drug VX-770 would prevent mucus from forming in the first
place. For younger patients, or those with milder cases, the drug could provide
the closest thing to a cure, the Salt Lake City Tribune reported Monday.

The trial for VX-770 focuses on a mutation that affects only about 2 percent of
the people with cystic fibrosis, but the researchers say they hope they could
adapt the drug to work for a wider population.



URL: www.upi.com


Copyright 2009 by United Press International

Disclaimer: References or links to other sites from Wellness.com does not constitute recommendation or endorsement by Wellness.com. We bear no responsibility for the content of websites other than Wellness.com.
Community Comments
Be the first to comment.